Switching CGRP(r) MoAbs in migraine: what evidence?

References

• Stovner LJ, Hagen K, Linde M, et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022 Apr 12;23(1):34. doi: 10.1186/s10194-022-01402-2
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1–211. doi: 10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019 Jan 1;99(1):17–24.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002 Sep;22(7):491–512. doi: 10.1046/j.1468-2982.2002.00386.x
   PubMed Web of Science ®Google Scholar
• Ailani J, Burch RC, Robbins MS. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021–1039. doi: 10.1111/head.14153
   PubMed Web of Science ®Google Scholar
• Tzankova V, Becker WJ, Chan TLH. Pharmacologic prevention of migraine. CMAJ. 2023 Feb 6;195(5):E187–e192. doi: 10.1503/cmaj.221607
   PubMed Web of Science ®Google Scholar
• Lipton RB, Nicholson RA, Reed ML, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62(2):122–140. doi: 10.1111/head.14259
   PubMed Web of Science ®Google Scholar
• Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501–514. doi: 10.1038/s41582-021-00509-5
   PubMed Web of Science ®Google Scholar
• Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022 Jun 11;23(1):67. doi: 10.1186/s10194-022-01431-x
   PubMed Web of Science ®Google Scholar
• Martelletti P, Giamberardino MA. Advances in orally administered pharmacotherapy for the treatment of migraine. Expert Opin Pharmacother. 2019 Jan 22;20(2):209–218. doi: 10.1080/14656566.2018.1549223
   PubMed Web of Science ®Google Scholar
• Kung D, Rodriguez G, Evans R. Chronic migraine: diagnosis and management. Neurol Clin. 2023 Feb;41(1):141–159. doi: 10.1016/j.ncl.2022.05.005
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017 Jan;57(1):165–178. doi: 10.1111/head.12997
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European headache federation. J Headache Pain. 2018 Sep 26;19(1):91. doi: 10.1186/s10194-018-0921-8
   PubMedGoogle Scholar
• Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022 Jun 4;27(1):86. doi: 10.1186/s40001-022-00716-w
   PubMed Web of Science ®Google Scholar
• Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Sep 2;402(10404):775–785. doi: 10.1016/S0140-6736(23)01049-8
   PubMed Web of Science ®Google Scholar
• Cho S, Kim BK. Update of gepants in the treatment of chronic migraine. Curr Pain Headache Rep. 2023 Oct;27(10):561–569. doi: 10.1007/s11916-023-01167-6
   PubMed Web of Science ®Google Scholar
• Al-Hassany L, Lyons HS, Boucherie DM, et al. The sense of stopping migraine prophylaxis. J Headache Pain. 2023 Feb 16;24(1):9. doi: 10.1186/s10194-023-01539-8
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Sawyer J, et al. Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. Headache. 2001 Oct;41(9):854–861. doi: 10.1111/j.1526-4610.2001.01156.x
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Fitzek M, Overeem LH, et al. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 2023 Feb 27;24(1):16. doi: 10.1186/s10194-023-01552-x
   PubMed Web of Science ®Google Scholar
• Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009 May;84(5):422–435. doi: 10.1016/S0025-6196(11)60561-2
   PubMed Web of Science ®Google Scholar
• Moskatel LS, Graber-Naidich A, He Z, et al. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: a retrospective, observational analysis. Headache. 2023 Oct 26;64(2):188–194. doi: 10.1111/head.14642
   PubMed Web of Science ®Google Scholar
• Muddam MR, Obajeun OA, Abaza A, et al. Efficacy and Safety of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in preventing migraines: a systematic review. Cureus. 2023 Sep;15(9):e45560. doi: 10.7759/cureus.45560
   PubMed Web of Science ®Google Scholar
• Vernieri F, Brunelli N, Messina R, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021 Dec 18;22(1):154. doi: 10.1186/s10194-021-01363-y
   PubMed Web of Science ®Google Scholar
• Messina R, Huessler EM, Puledda F, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. 2023 Mar;43(3):3331024231152169. doi: 10.1177/03331024231152169
   Web of Science ®Google Scholar
• Silberstein SD, Reshef S, Cohen JM, et al. Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther. 2023 Feb;40(2):445–459. doi: 10.1007/s12325-022-02346-4
   PubMed Web of Science ®Google Scholar
• Barbanti P, Aurilia C, Egeo G, et al. Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study. Neurology. 2023 Sep 12;101(11):482–488. doi: 10.1212/WNL.0000000000207292
   PubMedGoogle Scholar
• Barbanti P, Egeo G, Aurilia C, et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022 Nov 1;23(1):138. doi: 10.1186/s10194-022-01498-6
   PubMed Web of Science ®Google Scholar
• Waliszewska-Prosół M, Vuralli D, Martelletti P. What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? J Headache Pain. 2023 Dec 05;24(1):163. doi: 10.1186/s10194-023-01698-8
   PubMed Web of Science ®Google Scholar
• Garg S, Vij M, Edward N, et al. Erenumab: a novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention. J Anaesthesiol Clin Pharmacol. 2020 Jan;36(1):104–109. doi: 10.4103/joacp.JOACP_3_19
   PubMed Web of Science ®Google Scholar
• Hoy SM. Fremanezumab: first global approval. Drugs. 2018 Nov;78(17):1829–1834. doi: 10.1007/s40265-018-1004-5
   PubMed Web of Science ®Google Scholar
• Martin V, Samaan KH, Aurora S, et al. Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review. Adv Ther. 2020 May;37(5):2034–2049. doi: 10.1007/s12325-020-01319-9
   PubMed Web of Science ®Google Scholar
• Ziegeler C, Mehnert J, Asmussen K, et al. Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology. 2020 Nov 17;95(20):e2794–e2802. doi: 10.1212/WNL.0000000000010740
   PubMed Web of Science ®Google Scholar
• Basedau H, Sturm LM, Mehnert J, et al. Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study. Elife. 2022 May 23;11:11. doi: 10.7554/eLife.77146
   Web of Science ®Google Scholar
• de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018 May;103(5):815–825. doi: 10.1002/cpt.799
   PubMed Web of Science ®Google Scholar
• Kielbasa W, Quinlan T. Population pharmacokinetics of galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol. 2020 Feb;60(2):229–239. doi: 10.1002/jcph.1511
   PubMed Web of Science ®Google Scholar
• Fiedler-Kelly JB, Cohen-Barak O, Morris DN, et al. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Br J Clin Pharmacol. 2019 Dec;85(12):2721–2733. doi: 10.1111/bcp.14096
   PubMed Web of Science ®Google Scholar
• Ziegeler C, May A. Non-responders to treatment with antibodies to the CGRP-Receptor may profit from a switch of antibody class. Headache. 2020;60(2):469–470. doi: 10.1111/head.13729
   PubMed Web of Science ®Google Scholar
• Overeem LH, Peikert A, Hofacker MD, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia. 2022 Apr;42(4–5):291–301. doi: 10.1177/03331024211048765
   PubMed Web of Science ®Google Scholar
• Lambru G, Caponnetto V, Hill B, et al. Long-term effect of switching from an anti-CGRP receptor to an anti-CGRP ligand antibody in treatment-refractory chronic migraine: a prospective real-world analysis. Neurotherapeutics. 2023 Sep;20(5):1284–1293. doi: 10.1007/s13311-023-01394-0
   PubMed Web of Science ®Google Scholar
• Suzuki S, Suzuki K, Shiina T, et al. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285. doi: 10.3389/fneur.2023.1220285
   PubMed Web of Science ®Google Scholar
• Straube A, Broessner G, Gaul C, et al. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the finesse study. J Headache Pain. 2023;24(1). doi: 10.1186/s10194-023-01593-2
   Web of Science ®Google Scholar
• Ihara K, Ohtani S, Watanabe N, et al. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing. J Neurol Sci. 2023 Oct 15;453:120811. doi: 10.1016/j.jns.2023.120811
   PubMed Web of Science ®Google Scholar
• Overeem LH, Lange KS, Fitzek MP, et al. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol. 2023;14:1154420. doi: 10.3389/fneur.2023.1154420
   PubMed Web of Science ®Google Scholar
• Suzuki K, Suzuki S, Shiina T, et al. Real-world effectiveness of erenumab in Japanese patients with migraine. Heliyon. 2024 Feb 29;10(4):e26568. doi: 10.1016/j.heliyon.2024.e26568
   PubMed Web of Science ®Google Scholar
• Iannone LF, Burgalassi A, Vigani G, et al. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia. 2023 Apr;43(4):3331024231160519. doi: 10.1177/03331024231160519
   Web of Science ®Google Scholar
• Gorantla S, Gopireddy MMR, Bhat A, et al. Placebo response with subcutaneous injections in calcitonin gene-related peptide receptor monoclonal antibody migraine preventative trials – a systematic review and meta-analysis. Cephalalgia Reports. 2022 Jan 01;5:25158163221120103. doi: 10.1177/25158163221120103
   Google Scholar
• Tepper SJ, Cirillo J, Kim E, et al. The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression. J Headache Pain. 2023 May 16;24(1):54. doi: 10.1186/s10194-023-01587-0
   PubMed Web of Science ®Google Scholar
• Alegre-Del Rey E, Fénix-Caballero S, Domínguez-Santana C. Switching of anti-migraine antibodies: effectiveness or regression to the mean? Eur J Hosp Pharm. 2024 Feb 13:ejhpharm–2024. doi: 10.1136/ejhpharm-2024-004102
   PubMedGoogle Scholar